10 jili online casino

Biden says he was ‘stupid’ not to put his name on pandemic relief checks like Trump didTHOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE AmgenPelicans' Zion Williamson Shows off Full-Back Tattoo in Social Media Video10 jili online casino 。

HALIFAX, Nova Scotia (AP) — The first woman to command Canada's military called out a U.S. senator on Saturday for questioning the role of women in combat. Gen. Jennie Carignan responded to comments made by Idaho Republican Sen. Jim Risch , the ranking member of the U.S. Senate Foreign Relations Committee, who was asked on Friday whether President-elect Donald Trump’s nominee for defense secretary, Pete Hegseth , should retract comments that he believes men and women should not serve together in combat units . “I think it’s delusional for anybody to not agree that women in combat creates certain unique situations that have to be dealt with. I think the jury’s still out on how to do that," Risch said during a panel session at the Halifax International Security Forum on Friday. Carignan, Canada's chief of defense staff and the first woman to command the armed forces of any Group of 20 or Group of Seven country, took issue with those remarks during a panel session on Saturday. "If you’ll allow me, I would first like maybe to respond to Senator Risch’s statement yesterday about women in combat because I wouldn’t want anyone to leave this forum with this idea that women are a distraction to defense and national security," Carignan said. “After 39 years of career as a combat arms officer and risking my life in many operations across the world, I can’t believe that in 2024, we still have to justify the contribution of women to their defense and to their service, in their country. I wouldn’t want anyone to leave this forum with this idea that this is that it is some kind of social experiment.” Carignan said women have participating in combat for hundreds of years but have never been recognized for fighting for their country. She noted the women military personnel in the room. “All the women sitting here in uniform, stepping in, and deciding to get into harm’s way and fight for their country, need to be recognized for doing so," she said. “So again, this is the distraction, not the women themselves." Carignan received a standing ovation at the forum, which attracts defense and security officials from Western democracies. Hegseth has reignited a debate that many thought had been long settled: Should women be allowed to serve their country by fighting on the front lines? The former Fox News commentator made it clear, in his own book and in interviews, that he believes men and women should not serve together in combat units . If Hegseth is confirmed by the Senate, he could try to end the Pentagon’s nearly decade-old practice of making all combat jobs open to women. Hegseth’s remarks have generated a barrage of praise and condemnation. Carignan was promoted to the rank of general during the change-of-command ceremony this past summer, after being chosen by Prime Minister Justin Trudeau’s government to become Canada’s first female defense chief. Carignan is no stranger to firsts. She was also the first woman to command a combat unit in the Canadian military, and her career has included deployments to Iraq, Afghanistan, Bosnia and Syria. For the last three years, she has been the chief of professional conduct and culture, a job created as a result of the sexual misconduct scandal in 2021. Her appointment this year comes as Canada continues to face criticism from NATO allies for not spending 2% of its gross domestic product on defense. The Canadian government recently said that it would reach its NATO commitment by 2032. Risch said Friday Trump would laugh at Canada’s current military spending plans and said the country must do more. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!

Liberals’ holiday tax break and cash giveaway has winners and losersNone

None

The Committee for Foreign Investment in the United States has been reviewing the deal, which has faced political opposition from both parties. It has been looking into whether it would raise any national security concerns, such as by further weaking America's steelmaking capacity. Bloomberg News cited sources familiar with the matter who said President Joe Biden would block the deal after the CFIUS report came back this month. Nippon Steel said it would maintain U.S. Steel as a subsidiary that would remain headquartered in Pittsburgh. It has promised no layoffs or plant closings and said it would invest $2.7 billion in U.S. Steel plants, including $300 million in a blast furnace in Gary Works. The Japan-based steelmaker has threatened legal action if the deal is blocked. Listen now and subscribe: Apple Podcasts | Spotify | RSS Feed | SoundStack | All Of Our Podcasts "Nippon Steel is confident that our proposed partnership is the best path forward to secure the future of U. S. Steel," Nippon Steel spokesman Jack Coster said. "From the outset of the process, we have engaged in good faith with all parties to underscore how the transaction will bolster American economic and national security by countering the threats posed by China. It is inappropriate that politics continue to outweigh true national security interests – especially with the indispensable alliance between the U.S. and Japan as the important foundation. Nippon Steel still has confidence in the justice and fairness of America and its legal system, and — if necessary — will work with U. S. Steel to consider and take all available measures to reach a fair conclusion." The incoming Trump administration also has threatened to block the merger. The United Steelworkers union has raised a number of concerns, including that it would erode American steelmaking over time and make it harder to prosecute trade cases. It notes that the United States currently imposes tariffs on some imports from Nippon Steel and expresses fears more of the steelmaking would happen abroad, reducing U.S. Steel's mills to finishing lines. U.S. Steel spokeswoman Amanda Malkowski said the deal would benefit all stakeholders, including "the future of steelmaking in Indiana." "The transaction with Nippon Steel provides, by far, the brightest future for U. S. Steel, our employees and communities, and our customers," Malkowski said. "Nippon Steel has committed to preserve U. S. Steel as a U.S. company headquartered in Pennsylvania and to contribute billions of dollars of investment to our mills and communities, securing the future of steelmaking in Pennsylvania and Indiana. No other party can do this. Investment into the United States advances U.S. national security by enhancing innovation and competitiveness in the United States and bolstering critical global alliances. This transaction should be approved on its merits. The benefits are overwhelmingly clear. Our communities, customers, investors, and employees strongly support this transaction, and we will continue to advocate for them and adherence to the rule of law."Rutgers' attempt to ice kicker backfires as Illinois hits 40-yard game-winning TD on next play

COPPELL, Texas (AP) — COPPELL, Texas (AP) — Dave & Buster's Entertainment Inc. (PLAY) on Tuesday reported a loss of $32.7 million in its fiscal third quarter. The Coppell, Texas-based company said it had a loss of 84 cents per share. Losses, adjusted for one-time gains and costs, were 45 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. The owner of Dave & Buster's, a chain of restaurants and arcades posted revenue of $453 million in the period, which also missed Street forecasts. Six analysts surveyed by Zacks expected $459.9 million. This story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on PLAY at https://www.zacks.com/ap/PLAY

Flag football uses talent camps to uncover new starsPelicans' Zion Williamson Shows off Full-Back Tattoo in Social Media Video

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.

What both sides are saying about ceasefire deal between Israel and HezbollahTrump names Andrew Ferguson as head of Federal Trade Commission to replace Lina Khan